In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

Enter: “Your Cancer Is Our Challenge,” a new initiative that GSK ... adding that they round out GSK’s drug-based efforts to ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.

GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

A St. Louis-based clinical-stage biotechnology company developing cancer-fighting drugs has hired a new medical chief ...

Also, it is focusing more on oncology and the immune system, with genetic data to help develop the next generation of drugs. The benefits of these strategies are showing up in GSK's early-stage drugs.

GSK will pay $300 million to acquire a bispecific antibody from Shanghai-based Chimagen Biosciences that it believes has the ...

For GSK, the divestment of its entire marketed oncology portfolio is an eye-catching ... a new vaccine for prevention of meningitis B. The drug is the first-in-class, and has been given a ...

GSK did not admit wrongdoing in any of the cases. The company said in a statement to investors that while there is "no consistent or reliable evidence" the drug increases the risk of cancer ...

The drugmaker said sales of Arexvy fell sharply in the third quarter, but cancer and HIV treatments saw a stronger ...